Carole B. Miller

发表

Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.

J. Cortes, J. Lipton, J. Pinilla-Ibarz, 2016, Clinical lymphoma, myeloma & leukemia.

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

R. Larson, A. Saven, F. Mandelli, 2002, Blood.

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

M. Baccarani, F. Mandelli, P. Cony-Makhoul, 2002, The New England journal of medicine.

A Phase III, Randomized, Double-blind, Placebo-controlled, Multinational Trial of Iseganan for the Prevention of Oral Mucositis in Patients Receiving Stomatotoxic Chemotherapy (PROMPT-CT Trial)

T. Fleming, E. Anaissie, R. Beveridge, 2003, Leukemia & lymphoma.

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.

J. Lipton, Carole B. Miller, D. Vesole, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis

J. Dipersio, M. Arcasoy, H. Kantarjian, 2013, British journal of haematology.

Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.

S. Woolf, D. Cella, B. Djulbegovic, 2002, Blood.

Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.

A. Shields, H. Kantarjian, S. Verstovsek, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.

S. Woolf, D. Cella, B. Djulbegovic, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2013, Haematologica.

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies

T. Barbui, J. Dipersio, M. Arcasoy, 2014, Haematologica.

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Understanding United States (US) Treatment Practices for the Management of Chronic Myeloid Leukemia (CML) in Clinical Practice: A US Subgroup Analysis of the WORLD CML Registry.

J. Cortes, R. Hermann, Carole B. Miller, 2012 .

, MD , FACP Hypercalcemia of Malignancy in Hospitalized Patients

Carole B. Miller, I. Jibrin, G. Lawrence, 2006 .

Hypercalcemia of Malignancy in Hospitalized Patients

Carole B. Miller, I. Jibrin, G. Lawrence, 2006 .

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis COMFORT-I

S. Verstovsek, R. Mesa, Carole B. Miller, 2017, Clinical lymphoma, myeloma & leukemia.

Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy.

S. Verstovsek, A. Vannucchi, C. Harrison, 2017, Leukemia research.

Treating Anemia of Cancer with Darbepoetin Alfa Administered Every 4 Weeks: Final Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Cancer Patients Not Receiving Chemotherapy and/or Radiotherapy.

Carole B. Miller, D. Gordon, G. Nichols, 2006 .

Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.

Tom Lillie, Carole B. Miller, David Gordon, 2008, The oncologist.

Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey

R. Mesa, Xiaomei Ma, Carole B. Miller, 2016, BMC Cancer.

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.

Kaori Ito, A. Mead, Jennifer A. Smith, 2020, Blood advances.

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.

Angela G. Fleischman, M. Arcasoy, T. Ganz, 2020, Blood advances.

Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey

R. Mesa, Xiaomei Ma, Carole B. Miller, 2016, Cancer.

Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2011 .

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.

M. Griesshammer, S. Verstovsek, M. Hino, 2020, The Lancet. Haematology.

Targeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia.

Carole B. Miller, M. Collins, G. Papadakis, 2020, The New England journal of medicine.

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

M. Cazzola, M. Griesshammer, S. Verstovsek, 2016, Haematologica.

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

J. Dipersio, M. Arcasoy, H. Kantarjian, 2017, Journal of Hematology & Oncology.

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2013, Haematologica.

Autologous bone marrow transplantation with 4‐hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10‐year experience

I. Flinn, S. Piantadosi, Richard J. Jones, 2002, British journal of haematology.

Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2012 .

Treatment of Invasive Fungal Infections in Renally Impaired Patients with Amphotericin B Colloidal Dispersion

E. Anaissie, G. Noskin, Carole B. Miller, 1998, Antimicrobial Agents and Chemotherapy.

Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib

J. Radich, D. DeAngelo, Carole B. Miller, 2017, Therapeutic advances in hematology.

Topoisomerase I 1 Levels and Drug Sensitivity in Adult Acute Myelogenous Leukemia

Leonard, Richard J. Jones, J. Karp, 2022 .

Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research

M. Horowitz, M. Bishop, Carole B. Miller, 2008, Bone Marrow Transplantation.

Evaluation of pain associated with oral mucositis during the acute period after administration of high‐dose chemotherapy

D. Cella, J. Wingard, F. Giles, 2003, Cancer.

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide

M. Griesshammer, S. Verstovsek, P. Guglielmelli, 2018, British journal of haematology.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Jason Gotlib, Moshe Talpaz, J. Dipersio, 2012, The New England journal of medicine.

Circulating clonotypic B cells in classic Hodgkin lymphoma.

M. Siedner, Richard J. Jones, Carole B. Miller, 2009, Blood.

Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.

C. Huff, Richard J. Jones, Carole B. Miller, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia

L. Zwelling, Richard J. Jones, J. Karp, 1994 .

Changes in Promoter Methylation and Gene Expression in Patients with MDS and MDS-AML Treated with 5-Azacitidine and Sodium Phenylbutyrate.

M. Grever, J. Herman, S. Baylin, 2004 .

Autotransplantation versus HLA‐matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research

J. Klein, M. Horowitz, R. Gale, 2006, British journal of haematology.

Oral Valacyclovir as Prophylaxis against Herpes Simplex Virus Reactivation During High Dose Chemotherapy for Leukemia

S. Piantadosi, R. Orlowski, S. Gore, 2004, Leukemia & lymphoma.

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

M. Griesshammer, S. Verstovsek, M. Hino, 2018, Blood.

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

M. Griesshammer, S. Verstovsek, M. Hino, 2017 .

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.

M. Grever, J. Herman, S. Baylin, 2006, Cancer research.

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.

D. Scheinberg, R. Stone, M. Kalaycio, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes.

J. Klein, J. Sierra, M. Horowitz, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.

M. Grever, L. Grochow, R. Donehower, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.

I. Flinn, S. de Vos, A. Pettitt, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate

J. Kowalski, K. Murphy, Richard J. Jones, 2010, Clinical Cancer Research.

Long-Term R esults o f B lood a nd M arrow T ransplantation for H odgkin's L ymphoma

I. Flinn, R. Abrams, S. Piantadosi, 2001 .

Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study.

J. Vose, J. Fay, S. Bhatia, 2003, Blood.

Mortality and Causes of Death of Patients with Polycythemia Vera: Analysis of the Reveal Prospective, Observational Study

Carole B. Miller, R. Scherber, Jingbo Yu, 2020, Blood.

K562/GM-CSF Vaccination Reduces Tumor Burden, Including Achieving Molecular Remissions, in Chronic Myeloid Leukemia (CML) Patients with Residual Disease on Imatinib Mesylate (IM).

J. Kowalski, K. Murphy, Richard J. Jones, 2005 .

Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide–total body irradiation versus busulphan–cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission

J. Klein, R. Gale, M. Trigg, 2002, British journal of haematology.

Autotransplants f or H odgkin's D isease i n P atients N ever Achieving R emission: A R eport F rom t he A utologous B lood and M arrow T ransplant R egistry

J. Armitage, P. Bierman, J. Vose, 2011 .

Refinements of Environmental Assessment During an Outbreak Investigation of Invasive Aspergillosis in a Leukemia and Bone Marrow Transplant Unit

A. Streifel, C. Thio, T. Perl, 2000, Infection Control & Hospital Epidemiology.

Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia

M. Grever, S. Piantadosi, W. Stock, 2005, American journal of hematology.

Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial

H. Deeg, S. Verstovsek, R. Mesa, 2021, Blood.

study : Presented in part at the 43rd Annual Meeting of The American chronic myelogenous leukemia in myeloid blast crisis: results of a phase II Imatinib induces hematologic and cytogenetic responses in patients with

R. Larson, F. Mandelli, N. Russell, 2013 .

Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2013 .

Nilotinib-Associated Molecular Responses Achieved in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients with a Suboptimal Molecular Response to Imatinib.

J. Radich, A. Yang, D. DeAngelo, 2009 .

Expand: a Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis and Baseline Platelet Counts Between 50 × 109/L and 99 × 109/L

S. Verstovsek, G. Barosi, A. Vannucchi, 2012 .

Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.

J. Dipersio, M. Arcasoy, H. Kantarjian, 2012 .

Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy

R. Mesa, Carole B. Miller, J. Mascarenhas, 2023, Expert opinion on pharmacotherapy.

The Effect of Ruxolitinib on White Blood Cell Counts in Patients with Polycythemia Vera: Results from the RESPONSE Trial

M. Griesshammer, S. Verstovsek, A. Vannucchi, 2015 .

Addison's disease from non-Hodgkin's lymphoma with normal-size adrenal glands.

Carole B. Miller, G. Lawrence, Catherine K. Park, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).

Sonali M. Smith, B. Cheson, Carole B. Miller, 2018 .

Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma

I. Flinn, A. Pettitt, Weiliang Shi, 2016 .

Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF,

A. Shields, J. Dipersio, H. Kantarjian, 2011 .

Decreased erythropoietin response in patients with the anemia of cancer.

S. Piantadosi, Richard J. Jones, Carole B. Miller, 1990, The New England journal of medicine.

Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation.

S. Goodman, S. Goodman, Richard J. Jones, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term results of blood and marrow transplantation for Hodgkin's lymphoma.

I. Flinn, R. Abrams, S. Piantadosi, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.

J. Armitage, P. Bierman, J. Vose, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation.

F. Spijkervet, G. Oster, M. Horowitz, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).

J. Dipersio, H. Kantarjian, S. Verstovsek, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Practical Measures of Clinical Benefit with Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I

S. Verstovsek, R. Mesa, Carole B. Miller, 2014 .

Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia.

D. Ettinger, M. Ratain, L. Platanias, 1992, Journal of the National Cancer Institute.

Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.

M. Ratain, L. Platanias, Richard J. Jones, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy.

S. Verstovsek, A. Vannucchi, C. Harrison, 2017, Leukemia research.

Phase I study of combination drug purging for autologous bone marrow transplantation.

S. Piantadosi, Richard J. Jones, Carole B. Miller, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.